Shanghai MicroPort Endovascular MedTech Co., Ltd, a Chinese endovascular device manufacturer listed on the Shanghai Stock Exchange (SHA: 688016), has received a Category III medical device license from China’s National Medical Products Administration (NMPA) for its venous stent system. This product was granted special review status as an innovative medical device in China in 2021, recognizing its potential to address significant clinical needs.
The venous stent system is indicated for the treatment of non-thrombotic iliac vein compression syndrome, deep vein thrombosis, and post-thrombotic syndrome. The approval marks a significant advancement in the company’s efforts to provide innovative solutions for vascular diseases.- Flcube.com
